A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.

NCT00197041 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
2022
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

GlaxoSmithKline